Targeting tumours by adoptive transfer of immune cells

Clinical and Experimental Pharmacology and Physiology

Volumn 33, Issue 5-6, 2006, Pages 569-574

  MacAry, P A ^a   Too, C T ^a   Dai, X ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Dendritic cells; Immunotherapy; T lymphocyte; Tumour

Indexed keywords

ALPHA INTERFERON; CD16 ANTIGEN; CD56 ANTIGEN; CD57 ANTIGEN; EPITOPE; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INVASION; CANCER STAGING; CELL MEDIATED CYTOTOXICITY; CELL SUSPENSION; COLORECTAL CANCER; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFICACY; EXPERIMENTAL MOUSE; HODGKIN DISEASE; HUMAN; HUMORAL IMMUNITY; IMMUNOCOMPETENT CELL; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MELANOMA; MULTIPLE MYELOMA; NASOPHARYNX CANCER; NONHUMAN; NONMYELOABLATIVE CONDITIONING; PROSTATE CANCER; REVIEW; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE;

ADOPTIVE TRANSFER; ANIMALS; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE SUBSETS; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 33745213587     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2006.04409.x     Document Type: Review

References (75)

1. Weiss DW. Reflections on tumor origin, immunogenicity, and immunotherapy. Cancer Immunol. Immunother. 1984 18 : 1 4.
2. Medzhitov R, Janeway Jr CA. Innate immunity: Impact on the adaptive immune response. Curr. Opin. Immunol. 1997 9 : 4 9.
3. Laheru DA, Pardoll DM, Jaffee EM. Genes to vaccines for immunotherapy: How the molecular biology revolution has influenced cancer immunology. Mol. Cancer Ther. 2005 4 : 1645 52.
4. Lane DP. Cell immortalization and transformation by the p53 gene. Nature 1984 312 : 596 7.
5. Hudolin T, Juretic A, Spagnoli GC et al. Immunohistochemical expression of tumor antigens MAGE-A1, MAGE-A3/4, and NY-ESO-1 in cancerous and benign prostatic tissue. Prostate 2006 66 : 13 18.
6. Urosevic M, Braun B, Willers J, Burg G, Dummer R. Expression of melanoma-associated antigens in melanoma cell cultures. Exp. Dermatol. 2005 14 : 491 7.
7. Collins JJ, Black PH. Specificity of the carcinoembryonic antigen (CEA). N. Engl. J. Med. 1971 285 : 175 6.
8. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987 235 : 177 82.
9. Rakha EA, Boyce RW, Abd El-Rehim D et al. Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod. Pathol. 2005 18 : 1295 304.
10. Ablashi DV, Easton JM, Guegan JH. Herpesviruses and cancer in man and subhuman primates. Biomedicine 1976 24 : 286 305.
11. Gallo RC, Meyskens Jr FL. Advances in the viral etiology of leukemia and lymphoma. Semin. Hematol. 1978 15 : 379 98.
12. Kurth R, Fenyo EM, Klein E, Essex M. Cell-surface antigens induced by RNA tumour viruses. Nature 1979 279 : 197 201.
13. Chapman AL, Rickinson AB. Epstein-Barr virus in Hodgkin's disease. Ann. Oncol. 1998 9 ( Suppl. 5 S5 16.
14. Keegan TH, Glaser SL, Clarke CA et al. Epstein-Barr virus as a marker of survival after Hodgkin's lymphoma: A population-based study. J. Clin. Oncol. 2005 23 : 7604 13.
15. Hammerschmidt W, Sugden B. Epstein-Barr virus sustains Burkitt's lymphomas and Hodgkin's disease. Trends Mol. Med. 2004 10 : 331 6.
16. Rickinson AB, Murray RJ, Brooks J, Griffin H, Moss DJ, Masucci MG. T cell recognition of Epstein-Barr virus associated lymphomas. Cancer Surv. 1992 13 : 53 80.
17. Ren Q, Sato H, Murono S, Furukawa M, Yoshizaki T. Epstein-Barr virus (EBV) latent membrane protein 1 induces interleukin-8 through the nuclear factor-kappa B signaling pathway in EBV-infected nasopharyngeal carcinoma cell line. Laryngoscope 2004 114 : 855 9.
18. + T-cell responses in healthy virus carriers. Tissue Antigens 2005 65 : 539 43.
19. Li X, Yang X, Jiang Y, Liu J. A novel HBV DNA vaccine based on T cell epitopes and its potential therapeutic effect in HBV transgenic mice. Int. Immunol. 2005 17 : 1293 302.
20. Miller AM, Pisa P. Tumor escape mechanisms in prostate cancer. Cancer Immunol. Immunother. 2005 1 7.
21. Thomas DA, Massague J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 2005 8 : 369 80.
22. Wiendl H, Mitsdoerffer M, Hofmeister V et al. A functional role of HLA-G expression in human gliomas: An alternative strategy of immune escape. J. Immunol. 2002 168 : 4772 80.
23. Tada T, Ohzeki S, Utsumi K et al. Transforming growth factor-beta-induced inhibition of T cell function. Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state. J. Immunol. 1991 146 : 1077 82.
24. Aractingi S, Kanitakis J, Euvrard S, Le Danff C, Carosella ED. Selective expression of HLA-G in malignant and premalignant skin specimens in kidney transplant recipients. Int. J. Cancer 2003 106 : 232 5.
25. Yamamura M, Modlin RL, Ohmen JD, Moy RL. Local expression of antiinflammatory cytokines in cancer. J. Clin. Invest. 1993 91 : 1005 10.
26. Wang E, Panelli MC, Marincola FM. Understanding the response to immunotherapy in humans. Springer Semin. Immunopathol. 2005 27 : 105 17.
27. Ahmad M, Rees RC, Ali SA. Escape from immunotherapy: Possible mechanisms that influence tumor regression/progression. Cancer Immunol. Immunother. 2004 53 : 844 54.
28. MacLennan IC, Gale DG, Wood J. Resistance of certain leukaemic myeloblasts to immunological attack. Int. J. Cancer 1975 15 : 995 9.
29. + T lymphocytes but not inhibition of angiogenesis. J. Immunother. 2005 28 : 343 51.
30. von Holzen U, Adamina M, Bolli M et al. Selective responsiveness to common gamma chain cytokines in peripheral blood-derived cytotoxic T lymphocytes induced by Melan-A/MART-1 (27-35) targeted active specific immunotherapy. Int. J. Cancer 2005 115 : 248 55.
31. Toze CL, Galal A, Barnett MJ et al. Myeloablative allografting for chronic lymphocytic leukemia: Evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease. Bone Marrow Transplant. 2005 36 : 825 30.
32. Boldt DH, Mills BJ, Gemlo BT et al. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans. Cancer Res. 1988 48 : 4409 16.
33. Ho WY, Nguyen HN, Wolfl M, Kuball J, Greenberg PD. In vitro methods for generating CD8(+) T-cell clones for immunotherapy from the naive repertoire. J. Immunol. Methods 2006 310 : 40 52.
34. Freedman RS, Tomasovic B, Templin S et al. Large-scale expansion in interleukin-2 of tumor-infiltrating lymphocytes from patients with ovarian carcinoma for adoptive immunotherapy. J. Immunol. Methods 1994 167 : 145 60.
35. Antonia S, Mule JJ, Weber JS. Current developments of immunotherapy in the clinic. Curr. Opin. Immunol. 2004 16 : 130 6.
36. Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J. Immunother. 2003 26 : 332 42.
37. Abe Y, Van Eden M, Gatanaga M et al. The role of lymphotoxin in the IL-2-driven differentiation of human lymphokine-activated T-killer (T-LAK) cells in vitro. Lymphokine Cytokine Res. 1993 12 : 279 83.
38. Schwartzentruber DJ, Hom SS, Dadmarz R et al. In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2. J. Clin. Oncol. 1994 12 : 1475 83.
39. Dudley ME, Wunderlich JR, Robbins PF et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002 298 : 850 4.
40. Kawai K, Saijo K, Oikawa T et al. Clinical course and immune response of a renal cell carcinoma patient to adoptive transfer of autologous cytotoxic T lymphocytes. Clin. Exp. Immunol. 2003 134 : 264 9.
41. Connor JP, Felder M, Hank J et al. Ex vivo evaluation of anti-EpCAM immunocytokine huKS-IL2 in ovarian cancer. J. Immunother. 2004 27 : 211 19.
42. Gillies SD, Lan Y, Williams S et al. An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma. Blood 2005 105 : 3972 8.
43. Comito MA, Sun Q, Lucas KG. Immunotherapy for Epstein-Barr virus-associated tumors. Leukemia Lymphoma 2004 45 : 1981 7.
44. Baxevanis CN, Sotiriadou NN, Gritzapis AD et al. Immunogenic HER-2/neu peptides as tumor vaccines. Cancer Immunol. Immunother. 2006 55 : 85 95.
45. Podack ER. Molecular mechanisms of cytolysis by complement and by cytolytic lymphocytes. J. Cell Biochem. 1986 30 : 133 70.
46. Grimm EA, Owen-Schaub L. The IL-2 mediated amplification of cellular cytotoxicity. J. Cell Biochem. 1991 45 : 335 9.
47. Mitchell MS, Darrah D, Yeung D et al. Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope. J. Clin. Oncol. 2002 20 : 1075 86.
48. Cho HI, Hong YS, Lee MA et al. Adoptive transfer of Epstein-Barr virus-specific cytotoxic T-lymphocytes for the treatment of angiocentric lymphomas. Int. J. Hematol. 2006 83 : 66 73.
49. + T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 2005 174 : 2591 601.
50. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 1994 179 : 1109 18.
51. MacAry PA, Lindsay M, Scott MA, Craig JI, Luzio JP, Lehner PJ. Mobilization of MHC class I molecules from late endosomes to the cell surface following activation of CD34-derived human Langerhans cells. Proc. Natl Acad. Sci. USA 2001 98 : 3982 7.
52. Santin AD, Bellone S, Palmieri M et al. HPV16/18, E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. Gynecol. Oncol. 2006 100 : 469 78.
53. Liau L, Prins R, Kiertscher S et al. Assessment of fusion cells from patient-derived ovarian carcinoma cells and dendritic cells as a vaccine for clinical use. Gynecol. Oncol. 2005 99 : 462 71.
54. Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 1998 4 : 328 32.
55. Panelli MC, Wunderlich J, Jeffries J et al. Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. J. Immunother. 2000 23 : 487 98.
56. Sadanaga N, Nagashima H, Mashino K et al. Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin. Cancer Res. 2001 7 : 2277 84.
57. Loveland BE, Zhao A, White S et al. Mannan-MUC1-pulsed dendritic cell immunotherapy: A phase I trial in patients with adenocarcinoma. Clin. Cancer Res. 2006 12 : 869 77.
58. Titzer S, Christensen O, Manzke O et al. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: Immunological and clinical aspects. Br. J. Haematol. 2000 108 : 805 16.
59. Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J. Clin. Oncol. 1999 17 : 968 75.
60. Jager D, Karbach J, Pauligk C et al. Humoral and cellular immune responses against the breast cancer antigen NY-BR-1: Definition of two HLA-A2 restricted peptide epitopes. Cancer Immun. 2005 5 : 11 17.
61. Ayyoub M, Stevanovic S, Sahin U et al. Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma. J. Immunol. 2002 168 : 1717 22.
62. Neumann F, Wagner C, Stevanovic S et al. Identification of an HLA-DR-restricted peptide epitope with a promiscuous binding pattern derived from the cancer testis antigen HOM-MEL-40/SSX2. Int. J. Cancer 2004 112 : 661 8.
63. Weihrauch MR, Ansen S, Jurkiewicz E et al. Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer. Clin. Cancer Res. 2005 11 : 5993 6001.
64. Mizukoshi E, Nakamoto Y, Tsuji H, Yamashita T, Kaneko S. Identification of alpha-fetoprotein-derived peptides recognized by cytotoxic T lymphocytes in HLA-A24+ patients with hepatocellular carcinoma. Int. J. Cancer 2006 118 : 1194 204.
65. Rohn TA, Reitz A, Paschen A et al. A novel strategy for the discovery of MHC class II-restricted tumor antigens: Identification of a melanotransferrin helper T-cell epitope. Cancer Res. 2005 65 : 10 68 78.
66. Maecker B, von Bergwelt-Baildon MS, Anderson KS et al. Rare naturally occurring immune responses to three epitopes from the widely expressed tumour antigens hTERT and CYP1B1 in multiple myeloma patients. Clin. Exp. Immunol. 2005 141 : 558 62.
67. Matsueda S, Takedatsu H, Yao A et al. Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles. Clin. Cancer Res. 2005 11 : 6933 43.
68. Kobayashi H, Nagato T, Oikawa K et al. Recognition of prostate and breast tumor cells by helper T lymphocytes specific for a prostate and breast tumor-associated antigen, TARP. Clin. Cancer Res. 2005 11 : 3869 78.
69. Oehlrich N, Devitt G, Linnebacher M et al. Generation of RAGE-1 and MAGE-9 peptide-specific cytotoxic T-lymphocyte lines for transfer in patients with renal cell carcinoma. Int. J. Cancer 2005 117 : 256 64.
70. Fisk B, Blevins TL, Wharton JT, Ioannides CG. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J. Exp. Med. 1995 181 : 2109 17.
71. Sun Z, Lethe B, Zhang Y et al. A new LAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-A68 tumors. Cancer Immunol. Immunother. 2005 55 : 644 52.
72. Ottaviani S, Colau D, van der Bruggen P, der Bruggen PV. A new MAGE-4 antigenic peptide recognized by cytolytic T lymphocytes on HLA-A24 carcinoma cells. Cancer Immunol. Immunother. 2005 55 : 867 72.
73. Okumura H, Noguchi Y, Uenaka A et al. Identification of an HLA-A24-restricted OY-TES-1 epitope recognized by cytotoxic T-cells. Microbiol. Immunol. 2005 49 : 1009 16.
74. Andersen MH, Pedersen LO, Capeller B, Brocker EB, Becker JC, thor Straten P. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res. 2001 61 : 5964 8.
75. Rezvani K, Brenchley JM, Price DA et al. T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: Identification, quantification, and characterization. Clin. Cancer Res. 2005 11 : 8799 807.